Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Maze Therapeutics (MAZE)
-
-
-
-
-
-
-
Leerink Partners on Maze Therapeutics (MAZE): Ph2 results confirm 'best-in-class' profile
-
-
-
-
-
-
-
Maze Therapeutics (MAZE) files mixed shelf
-
-
-
-
-
-
-
Maze Therapeutics presents drug data at kidney conference
-
-
-
-
-
-
-
Maze Therapeutics (MAZE) PT Raised to $34 at Leerink Partners
-
-
-
-
-
-
-
Guggenheim Starts Maze Therapeutics (MAZE) at Buy
-
-
-
-
471,230 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


